Here, we performed focussed cis-MR analysis with genetic variants from PPM1K, DBT and BCAT2 gene regions as instruments to directly assess the potential therapeutic effect of inhibiting BCKDK kinase on reducing T2D risk. This evidence concerns the gene BCAT2 and type 2 diabetes mellitus.